Sanofi Gets Approval For SU-type Amaryl ODTs
This article was originally published in PharmAsia News
Executive Summary
Sanofi announced Aug. 16 it received approval for sulphonylurea oral hypoglycemic agent Amaryl (glimepiride) for Type II diabetes in 0.5mg orally disintegrating tablets.